Combination L-T3 and L-T4 therapy for hypothyroidism

Area of Science:

• Endocrinology
• Genetics
• Molecular Biology

Background:

• Levothyroxine (L-T4) monotherapy is standard for hypothyroidism, but its sufficiency is debated.
• Combined therapy with triiodothyronine (T3) has been explored but lacked strong justification.
• Recent genetic findings suggest a rationale for T3 addition in specific patient subgroups.

Purpose of the Study:

• To review the evidence for combined T4/T3 therapy in hypothyroidism.
• To explore the role of deiodinase gene polymorphisms in thyroid hormone metabolism.
• To identify potential patient subgroups who might benefit from T3 addition.

Main Methods:

• Review of existing literature on T4/T3 therapy and deiodinase function.
• Analysis of genetic studies on deiodinase polymorphisms, particularly D2 Thr92Ala.
• Correlation of genetic findings with thyroid hormone levels and clinical outcomes.

Main Results:

• Deiodinases are crucial for maintaining euthyroid state; genetic polymorphisms can alter thyroid hormone levels.
• The D2 Thr92Ala polymorphism is associated with reduced T4 to T3 activation in tissues.
• This polymorphism may link to obesity, altered thyroid-pituitary feedback, and treatment response.

Conclusions:

• While L-T4 monotherapy is recommended, consider D2 gene polymorphism in patients with persistent fatigue despite normalized TSH.
• A high free T4/free T3 ratio may suggest this polymorphism.
• Therapeutic trials of T3 addition could be considered for selected patients pending further trials.